TUBB and neoplasm: We further examined the expression array data of tumor biopsies from the patients that achieved a pCR after neoadjuvant taxane-based therapy and those with residual disease (non-pCR), we showed a downregulated expression of TUBB, TUBB3 and TUBB6 genes in the tumors from the patients with residual disease to taxane–based therapy compared to those with pCR.